Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.

Pharmacogenetics and genomics - 1 Jun 2007

Nakajima Miki, Komagata Sayaka, Fujiki Yuto, Kanada Yoshihiro, Ebi Hiromichi, Itoh Kuniaki, Mukai Hirofumi, Yokoi Tsuyoshi, Minami Hironobu

Abstract excerpt

OBJECTIVE: To evaluate the effects of genetic polymorphisms of drug metabolizing enzymes on the pharmacokinetics of cyclophosphamide and its active metabolite, 4-hydroxycyclophosphamide, and on the pharmacodynamics. EXPERIMENTAL DESIGN: One hundred and three Japanese patients with malignant lymphoma or breast cancer treated with cyclophosphamide (500-750 mg/m) participated in this study. The plasma concentrations...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aryl Hydrocarbon Hydroxylases
Share to Cyclophosphamide

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cytochrome P-450 CYP2B6

Share to DNA, Neoplasm

Share to Introns

Share to Lymphoma

Share to Oxidoreductases, N-Demethylating

Share to Pharmacogenetics

Source

Identifiers

PMID: 17502835
DOI: 10.1097/FPC.0b013e328045c4fb

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic polymorphisms of CYP2B6 affect the pharmacokinetics/pharmacodynamics of cyclophosphamide in Japanese cancer patients.PMID 17502835Read ↗

Cytochrome P450 Genetic Variations Can Predict mRNA Expression, Cyclophosphamide 4-Hydroxylation, and Treatment Outcomes in Chinese Patients With Non-Hodgkin's Lymphoma.Semantic proximity Read ↗

Genetic markers in CYP2C19 and CYP2B6 for prediction of cyclophosphamide's 4-hydroxylation, efficacy and side effects in Chinese patients with systemic lupus erythematosus.Semantic proximity Read ↗

Pharmacogenetics of cyclophosphamide in patients with hematological malignancies.Semantic proximity Read ↗

Effects of CYP2B6 genetic polymorphisms in patients receiving cyclophosphamide combination chemotherapy for breast cancer.Semantic proximity Read ↗

Association between CYP2B6 genetic variability and cyclophosphamide therapy in pediatric patients with neuroblastomaSemantic proximity Read ↗

The importance of both CYP2C19 and CYP2B6 germline variations in cyclophosphamide pharmacokinetics and clinical outcomesSemantic proximity Read ↗

Cyclophosphamide pharmacogenomics and their effect on its bioactivation and pharmacokineticsSemantic proximity Read ↗

Severe and prolonged cyclophosphamide-induced hepatotoxicity in a breast cancer patient carrying a CYP2B6*7 variant.Semantic proximity Read ↗

The role of polymorphic cytochrome P450 gene (CYP2B6) in B-chronic lymphocytic leukemia (B-CLL) incidence and outcome among Egyptian patients.Semantic proximity Read ↗

Association study of genetic polymorphism in ABCC4 with cyclophosphamide-induced adverse drug reactions in breast cancer patients.Semantic proximity Read ↗

Population pharmacokinetics analysis of cyclophosphamide with genetic effects in patients undergoing hematopoietic stem cell transplantation.Semantic proximity Read ↗

CYP3A4 and CYP3A5 Genes in Cyclophosphamide-treated Chronic Lymphocytic Leukemia Patients: A Pharmacogenetics Study.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.